ACE and heart failure: The groups were well matched for age: 52.9 ± 11.3 (IVB) vs 53.5 ± 11.8 years, sex: 57% male, heart failure with reduced ejection fraction diagnosis: 66.4%, comorbidities and goal-directed medical therapy: ß-adrenergic blockers 89.7%, angiotensin-converting enzyme inhibitors/angiotensin receptor antagonists/sacubitril/valsartan 79.4%, and mineral corticoid antagonists 39.3%.